Drugs / PCV15
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05489328 | Aug → Oct 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06731374 | Feb → Dec 2025 overdue | pneumococcal infection | University of Oxford | Recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT05696080 Comparator | Feb 2023 → Feb 2024 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05393037 Comparator | Jul 2022 → Jul 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05420961 Comparator | Jul 2022 → May 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV-15 | “One dose (0.5 ml) of PCV-15 is to be given Intramuscularly (IM) into the deltoid region of the arm at day 0.” NCT06731374 ↗ |
| Modality | Vaccine | “15-valent PCV (PCV15)” PMID 40953572 ↗ Sep 2025 |
| Route | Intramuscular | “Unmasked study personnel administered a 0·5 mL intramuscular dose of each vaccine.” PMID 40953572 ↗ Sep 2025 |